-
公开(公告)号：EP4446319A1
公开(公告)日：2024-10-16
申请号：EP23736981.4
申请日：2023-01-03
发明人： ZHANG, Qiang , YANG, Leifu
IPC分类号： C07D403/14 , A61K31/506 , A61K31/4245 , A61P35/00 , A61P37/00 , A61P17/00 , A61P1/00
摘要： Provided are a carbonyl bridged heterocyclic compound having a structure represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing these compounds, and an application of these compounds or composition in drug preparation. The compounds, the stereoisomer, the pharmaceutically acceptable salt thereof and the like can be used for treating or preventing autoimmune diseases, tumors and neurodegenerative diseases related to protein 1 kinase (RIPK1).
-
公开(公告)号：EP4438037A1
公开(公告)日：2024-10-02
申请号：EP24179001.3
申请日：2022-01-27
申请人： Priothera SAS , Priothera Limited
IPC分类号： A61K31/00 , A61K9/00 , A61K31/137 , A61K31/397 , A61K31/4245 , A61K31/426 , A61K45/06 , A61P35/00 , A61P35/02 , A61P37/06 , A61K31/436 , A61K31/519 , A61K31/5377 , A61K38/13 , A61K31/13
CPC分类号： A61K31/137 , A61K31/00 , A61K31/397 , A61K31/4245 , A61K31/426 , A61K45/06 , A61P35/00 , A61P35/02 , A61P37/06 , A61K31/5377 , A61K31/13 , A61K31/436 , A61K31/519
摘要： The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from acute myelogenous leukemia (AML) and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.
-
公开(公告)号：EP4415717A1
公开(公告)日：2024-08-21
申请号：EP22881955.3
申请日：2022-10-11
发明人： TAPINOS, Nikolaos , HASSAN, Ola , KARAMBIZI, David
IPC分类号： A61K31/4709 , A61K31/41 , A61K31/4245 , A61K31/47 , A61P35/00 , C07D271/02 , C07D271/06
CPC分类号： A61K31/41 , A61K31/4245 , A61K31/47 , A61K31/4709 , A61P35/00 , C07D271/06 , C07D413/04 , C07D413/14 , C07D498/10 , C07D413/06 , C07D413/10 , C07D471/04 , C07D519/00 , C07D403/04 , C07D487/04 , C07D491/052 , C07D413/12 , C07D417/12 , C07D417/04 , C07D403/10 , A61K31/713
-
公开(公告)号：EP4410286A1
公开(公告)日：2024-08-07
申请号：EP22875168.1
申请日：2022-09-30
发明人： ZHANG, Guimin , YAO, Jingchun , LI, Honghua , SUN, Chenghong , ZHAO, Tao
IPC分类号： A61K31/4245 , A61K31/352 , A61P25/28 , A61K9/08 , A61K9/10 , A61K9/107 , A61K9/113 , A61K9/14 , A61K9/16 , A61K9/22 , A61K9/24 , A61K9/28 , A61K9/48
CPC分类号： A61K9/209 , A61K31/4245 , A61K9/107 , A61K9/20 , A61K9/10 , A61K9/14 , A61K9/48 , A61K9/16 , A61K9/28 , A61K9/08 , A61K9/113 , A61P25/28 , A61K31/352
摘要： A pharmaceutical composition for preventing or treating Alzheimer's disease and use thereof are disclosed and belong to the technical field of medicines. The pharmaceutical composition includes
(Z)-3-(N-(3-bromo-4-fluorophenyl)-N'-hydroxyformamido)-4-(2-guanidinoethyl)amino)-1,2, 5-oxadiazole and anhydroicaritin. A pharmacodynamic experiment proves that the pharmaceutical composition achieves a synergistic therapeutic effect on treating Alzheimer's disease.-
公开(公告)号：EP4395781A1
公开(公告)日：2024-07-10
申请号：EP22863742.7
申请日：2022-08-30
发明人： HA, Nina , BAE, Daekwon , KIM, Min Cheol , SONG, Ju Young , SUH, Dong-hyeon , LEE, Suk Jin , BAEK, Jiyeon , PARK, Jin Sol
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/4245 , A61K31/454 , A61K31/541 , A61P25/02 , C07D271/10 , C07D413/12 , C07D471/10 , C07D491/107
CPC分类号： A61K31/4245 , A61K31/438 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P25/00 , A61P25/02 , C07D271/10 , C07D413/12 , C07D471/10 , C07D491/107 , A61K31/351 , A61K31/4523 , C07D413/04 , C07D413/14 , C07D417/12
-
公开(公告)号：EP4157834B1
公开(公告)日：2024-07-03
申请号：EP21732200.7
申请日：2021-05-27
IPC分类号： C07D413/12 , A61K31/422 , A61K31/4245 , A61K31/4025 , A61P35/00 , A61P25/00 , A61P25/28 , A61P3/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00
-
公开(公告)号：EP4326263A1
公开(公告)日：2024-02-28
申请号：EP22723295.6
申请日：2022-04-22
IPC分类号： A61K31/4245 , A61K31/427 , A61P9/04 , A61K31/165 , A61K31/422 , A61K31/437 , A61K31/44 , A61K31/505 , A61K31/506 , A61K31/519
-
公开(公告)号：EP3956324B1
公开(公告)日：2024-02-21
申请号：EP20717897.1
申请日：2020-04-16
发明人： VARA SALAZAR, Yosu Ion , ALDABA ARÉVALO, Eneko , BELLO IGLESIAS, Tamara , ROBERTS, Richard Spurring , SIMÓN BUELA, Laureano , BREA, José Manuel , CARRACEDO, Ángel , LOZA GARCÍA, María Isabel
IPC分类号： C07D413/14 , C07D413/10 , A61K31/4245 , A61P25/16 , A61P25/28 , A61P35/00 , A61P13/12
-
公开(公告)号：EP4248958A3
公开(公告)日：2024-01-03
申请号：EP23191736.0
申请日：2022-01-27
申请人： Priothera SAS , Priothera Limited
IPC分类号： A61K31/00 , A61K9/00 , A61K31/137 , A61K31/397 , A61K31/4245 , A61K31/426 , A61K45/06 , A61P35/00 , A61P35/02 , A61P37/06 , A61K31/436 , A61K31/519 , A61K31/5377 , A61K38/13 , A61K31/13
摘要： The present invention relates to S1P receptor modulators, preferably mocravimod, for use in treating patients suffering from acute myelogenous leukemia (AML) and who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The invention relates in particular to methods of treating AML in subjects undergoing HSCT, wherein said method comprises daily administering an efficient amount of S1P receptor modulator, preferably mocravimod, to said subject in need thereof, for at least 6 months, preferably at least 12 months.
-
公开(公告)号：EP4284348A2
公开(公告)日：2023-12-06
申请号：EP22702938.6
申请日：2022-01-27
申请人： Priothera SAS , Priothera Limited
IPC分类号： A61K31/00 , A61K9/00 , A61K31/137 , A61K31/397 , A61K31/4245 , A61K31/426 , A61K45/06 , A61P35/00 , A61P35/02 , A61P37/06 , A61K31/436 , A61K31/519 , A61K31/5377 , A61K38/13 , A61K31/13
-
-
-
-
-
-
-
-
-
搜索结果
1634 条记录 (耗时 0.022 秒)
